SOGROYA somapacitan-beco injection 5mg | 10mg | 15mg **Patient Enrollment Form | Pediatric**



Phone: 1-888-668-6444 Fax: 1-888-508-8200

Monday - Friday 8:00 AM to 8:00 PM ET

* Indicates a required field	New start	Reauthorization	Restarting treatment	Transitioning from:
------------------------------	-----------	-----------------	----------------------	---------------------

REQUESTED	 Sogroya® Device Training: □ In-person □ Virtual Starter Kit NovoCare® Savings Offer (if eligible). For complete terms and conditions, visit <u>SogroyaSavingsEligibility.com</u>. Terms and conditions of JumpStart™ require active, timely prescriber support of Prior Authorization and/or Appeal documentation submission. Patients who have been prescribed Sogroya® for an FDA-approved indication and who have commercial insurance may be eligible to receive a limited supply of free product from JumpStart™. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program. JumpStart™ product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product. No purchase necessary. 										
	Patient first name:*	Patient last	name:				DOB (MM/D	D/YYYY):*			
	Gender *:* 🗖 Male 🗆 Female 🛛 Preferred language: 🗖 English 🗖 Spanish 🗖 Other:										
	Home address (No P.O. box):				City:		State:	Zip:*			
	· · · ·				-			· · ·			
ON	Shipping address (If different from Home Address): City:						State:	Zip:*			
<u>_</u>	Email:					P	rimary phone:				
56	Primary guardian/caregiver.*			/DD/YYYY):		Relationsh	onship to patient:				
E						Relationsh					
RMATIO	Primary medical insurance: (Please attach a copy of the insurance card if ava	ailable)					Phone:				
2	Subscriber name:	Subscriber ID:				Policy/	group #:				
운	Secondary medical insurance:						Phone:				
Z											
4	Subscriber name:	Subscriber ID:				Policy/	group #:				
	Primary pharmacy insurance: (Please attach a copy of the insurance card if a	available)					Phone:				
	Rx # ID: Rx Group #:		Rx	PCN #:			Rx BIN #:				
		s mala as famala IIs			ampanias still require	that and of		a used for each of their men			
	[†] Novo Nordisk and its partners recognize that patients may not identify a Please indicate the gender on file with the patient's insurance company.	S male of Ternale. Ho	wever, ma	iny insurance of	companies suir require	e triat one or	these two helds b		nuers.		
	□ E23.0 - Hypopituitarism □ E23.1 - Drug-induced hypopituitarism □ E89.3 - Postprocedural hypopituitarism Other diagnosis: ICD-10 code and description: If requesting JumpStart™ please select both Prescription fields (required)* □ JumpStart™ Prescription □ Ongoing Prescription Sogroya® (somapacitan-beco) prefilled pen: NovoFine® Needles: □ 5mg □ 10mg □ 15mg □ Birections: I autocover® 30G (8mm) disposable safety needles □ 1 □ 2										
ы Ш	Inject mg SC once weekly Days Supply R	.011113									
Δ	Preferred pharmacy:		Pharm	acy Phone:			Pharmacy Fax:				
	Pharmacy address:		City:			State:		Zip:			
ιΞ	J ()	l stim test 1		GH s	tim test 2		IGF-1:				
SE	Weight (kg): Date:/ / Da	Date: /			e: / /		IGF BP-3:				
28		Agent:			Agent:						
S S	Glowth velocity (cm/y) Ag	jent		_ Agei	IL						
AS	Bone age: Date:/ / Re	sults:		_ Resu	Ilts:		MRI has been	completed: 🗖 Yes 🗖 No			
	Provide and the second s				License #:*						
	Prescriber name:*										
	Practice name: Of	fice contact:				Preferre	ed method of con	tact: 🛛 Phone 🗖 Fax 🗖	Email		
	#: Tax ID #:			NPI # *							
_	Phone:* Fax:*		Email.*								
IZATION								*			
F	Address:*		City:*			State:*		Zip:*			
AUTHORIZ	Prescriber release:* By signing below, I hereby certify that: (a) I am a licensed practitioner, in good standing under applicable state law; (b) the product being prescribed is to treat a diagnosis(es) consistent with indications and dosing described in the product's prescribing information; (c) the information I have provided on this enrollment form is, to the best of my knowledge, true, complete, and accurate in all respects; and (d) I have obtained the necessary authorization from the patient, or where appropriate the patient's parent, caregiver, and/or legal representative to use, disclose, share, and/or release the above-referenced information along with other protected health information (as defined in the Health Insurance Portability and Accountability Act of 1996 ("HIPAA")) for the sole purpose of providing patient assistance. Further, I appoint NovoCare®, on my behalf, to convey this prescription to the dispensing pharmacy. I will immediately notify Novo Nordisk Inc, its employees, or partners, including AssistRx, Inc. (collectively, "NovoCare®") if the above-named patient, or where appropriate the patient's parent, caregiver, and/or legal representative, revokes their consent to share their PHI with NovoCare®. I give you permission to contact me, or the above named patient/Caregiver, with any questions related to NovoCare®.										
	Prescriber signature (no signature stamps):*		Date:*								